Elevai Labs INC 8-K filings

Elevai Labs has entered into a one-year consulting agreement with Santorio Biomedical, securing the services of Mr. Deniel Mero to advise on biotechnology opportunities and strategic matters.

Elevai Labs has obtained an exclusive global license, excluding South Korea, to develop and commercialize two engineered probiotic assets targeting muscle loss and obesity.

Elevai Labs received a delisting notice from Nasdaq due to its stock price falling below the minimum bid requirement and appointed a new chair to its compensation committee following a director's resignation.

Elevai Labs has obtained a worldwide exclusive license for INmune Bio's EMx technology, enabling in-house production of mesenchymal stromal cells for cosmetic products.